While early, the findings suggest the therapy could be superior to Novartis’ Vijoice at treating “vascular anomalies,” a cluster of chronic conditions with few available treatments.
An article from
Dive Brief
While early, the findings suggest the therapy could be superior to Novartis’ Vijoice at treating “vascular anomalies,” a cluster of chronic conditions with few available treatments.
Published May 19, 2026
Relay Therapeutics is developing a medicine for a group of conditions known as vascular anomalies.
Relay Therapeutics Reports Early Success For Investigational Drug In Rare Vascular Disorders - Relay Ther
Relay's PI3Kα inhibitor clears efficacy bar in Phase 2 vascular anomalies study
A new ranking of pharma companies by R&D performance
Pfizer's next-gen pneumonia shot beats Prevnar 20; Relay targets $175M
Amplia takes aim at billion-dollar pancreatic cancer drug market
BeOne wins FDA approval in lymphoma race
JCR Pharmaceuticals Presents Preclinical Gene Therapy Data that Demonstrate Promising Central Nervous System Uptake at the American Society of Gene and Cell Therapy (ASGCT) 29th Annual Meeting
Relay Therapeutics reported early Phase 2 data showing lesion reduction and symptom improvement with zovegalisib.
Relay Therapeutics’ first data readout for zovegalisib in a rare genetic disease beat Wall Street expectations, expanding the…
Preliminary trials into Zorevunersen find drug to be safe and well tolerated by those with Dravet syndrome
Early trials have shown a massive reduction in seizures among young people with Dravet syndrome
A deal with Rigel Pharmaceuticals ends months of uncertainty about the future of Veppanu, a first-of-its-kind, newly approved…
The companies developing Ebvallo reached an agreement with the FDA to address its main reason for rejecting the drug.
